Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Evoxx Technologies GmbH. (7/21/16). "Press Release: Evoxx Technologies – Biotechnology for Healthy Nutrition". Monheim & Potsdam.

Organisations Organisation Evocatal GmbH
  Today Evoxx Technologies GmbH
  Group Advanced Enzyme Technologies (Advanced Enzymes) (Group)
  Organisation 2 Aevotis GmbH
  Group Advanced Enzyme Technologies (Advanced Enzymes) (Group)
Products Product foods, functional
  Product 2 industrial biotechnology
Persons Person Eggert, Thorsten (evocatal 201010 Managing Director / CEO)
  Person 2 Döring, Martina (aevotis 201011 Managing Director)

Biotechnology companies evocatal and aevotis have merged, forming evoxx technologies to focus on the development of enzymes and carbohydrate ingredients for the functional food market (nutritional health & wellness). A strong patent protected technology platform enables the development and marketing of exclusive carbohydrate oligomers /polymers for the global food market.

Monheim am Rhein and Potsdam, 21st July 2016. Following the acquisition of aevotis GmbH by evocatal GmbH in January 2015, the two are now legally merged and operating as evoxx technologies GmbH with the vision to become a leading provider of innovative enzyme and carbohydrate products for the food market (nutritional health & wellness). “In the functional food market we see an increasing demand for novel ingredients with strong scientifically supported health benefits”, describes Dr. Thorsten Eggert, Managing Director (CEO). In order to meet the needs of its customers, the food industry needs novel and multi-functional ingredients which are in line with recent scientific findings and studies on healthy diets. “The combination of convenience and health is required” states Martina Doering, Managing Director (CSO). “Modern consumers expect food delivering health benefits without changing taste and eating behavior” Ms. Doering continues.

evoxx technologies GmbH will use its competitive enzyme and carbohydrate development expertise in applications where high sugar content (sucrose, glucose, fructose, etc.) and/or inadequate amount of dietary fiber requires a solution. The company’s vision, as summarized by Dr. Eggert, is “within the next three years, evoxx will bring more healthy carbohydrates into the glass and onto the plate of the consumer by using enzymes and ingredients from the evoxx pipeline”.

Notwithstanding the new market focus, evoxx will ensure continuity in cooperative projects with customers and partners. The proprietary technology platform of evocatal and aevotis will still be applied by evoxx technologies to develop tailor-made enzymes and processes for various industries. evoxx technologies plans to enhance production capability to supply enzymes on an industrial scale for current and future customers.

About evoxx technologies GmbH

evoxx technologies GmbH, a German Industrial Biotechnology Company, is focusing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bioconversion. With its proprietary enzymes and carbohydrate ingredients, evoxx is active in high growth markets addressing consumer needs in the Global Food Health & Wellness Sector and Consumer Products Markets. Product development is based on the proprietary technology and patent platform covering the whole value chain from early enzyme and process development to industrial scale production and product deregulation. evoxx industrial partners and customers benefit from the unique metagenomics libraries, the enzyme and carbohydrate development skills and tech-transfer and production capabilities. evoxx is located on the Creative Campus in Monheim am Rhein and on the Biotech Campus Hermannswerder in Potsdam.

Contact Management

Dr. Thorsten Eggert
Managing Director, CEO
evoxx technologies GmbH
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
fon +49 2173 4099-411
fax +49 2173 4099-440

Martina Doering
Managing Director, CSO/ Business Development
evoxx technologies GmbH
Hermannswerder 20a
14473 Potsdam
fon +49 331 2000-110
fax +49 331 2000 111

Record changed: 2016-07-25


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Advanced Enzyme Technologies (Advanced Enzymes) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Hotspot for Startups 650x80px

» top